250 related articles for article (PubMed ID: 26220190)
41. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
42. Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?
Chan JY; Wang KH; Fang CL; Chen WY
PLoS One; 2014; 9(2):e89467. PubMed ID: 24558502
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex.
Boer K; Troost D; Jansen F; Nellist M; van den Ouweland AM; Geurts JJ; Spliet WG; Crino P; Aronica E
Neuropathology; 2008 Dec; 28(6):577-90. PubMed ID: 18410267
[TBL] [Abstract][Full Text] [Related]
44. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
45. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
[TBL] [Abstract][Full Text] [Related]
46. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
Palavra F; Robalo C; Reis F
Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
[TBL] [Abstract][Full Text] [Related]
47. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
48. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
49. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
50. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
Dabora SL; Jozwiak S; Franz DN; Roberts PS; Nieto A; Chung J; Choy YS; Reeve MP; Thiele E; Egelhoff JC; Kasprzyk-Obara J; Domanska-Pakiela D; Kwiatkowski DJ
Am J Hum Genet; 2001 Jan; 68(1):64-80. PubMed ID: 11112665
[TBL] [Abstract][Full Text] [Related]
51. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Davis PE; Peters JM; Krueger DA; Sahin M
Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
[TBL] [Abstract][Full Text] [Related]
52. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
53. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.
Magri L; Cambiaghi M; Cominelli M; Alfaro-Cervello C; Cursi M; Pala M; Bulfone A; Garcìa-Verdugo JM; Leocani L; Minicucci F; Poliani PL; Galli R
Cell Stem Cell; 2011 Nov; 9(5):447-62. PubMed ID: 22056141
[TBL] [Abstract][Full Text] [Related]
54. An Insight of Scientific Developments in TSC for Better Therapeutic Strategy.
Natarajan N; Thiruvenkatam V
Curr Top Med Chem; 2020; 20(23):2080-2093. PubMed ID: 32842942
[TBL] [Abstract][Full Text] [Related]
55. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
[TBL] [Abstract][Full Text] [Related]
56. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
57. TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.
Magini A; Polchi A; Di Meo D; Mariucci G; Sagini K; De Marco F; Cassano T; Giovagnoli S; Dolcetta D; Emiliani C
Hum Mol Genet; 2017 Sep; 26(17):3303-3312. PubMed ID: 28637240
[TBL] [Abstract][Full Text] [Related]
58. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
59. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
Tang X; Angst G; Haas M; Yang F; Wang C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
[TBL] [Abstract][Full Text] [Related]
60. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
